NDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
NAMENDA (memantine hydrochloride) by AbbVie is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for moderate to severe dementia of the alzheimer’s type. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAMENDA (memantine hydrochloride) is an oral small-molecule NMDA receptor antagonist approved for moderate to severe Alzheimer's disease dementia. It works by blocking glutamate-mediated excitotoxicity at NMDA receptors, though it does not prevent or slow neurodegeneration. The drug is indicated as a symptomatic treatment to help manage cognitive and functional decline in advanced Alzheimer's patients.
$0.063BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending signals a mature, contracting brand requiring cost-containment and defensive commercial strategies rather than growth investment.
Mechanism of Action
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
Indications (1)
Clinical Trials (2)
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Started Jun 2013
3,482 enrolled
Alzheimer's Desease
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Started Jul 2008
42 enrolled
Down Syndrome
Worked on NAMENDA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.